Table 2.

Association between a one standard deviation increase in baseline^* apolipoproteins and Lp(a) and cardiovascular events

Test	SD	Statin + Placebo				Statin + ERN				Int. P-value‡
		Hazard Ratio†	95% CI		P-value	Hazard Ratio†	95% CI		P-value
ApoB (mg/dl)	18.3	1.17	1.03	1.33	0.018	1.11	0.97	1.27	0.124	0.905
ApoA-1 (mg/dl)	16.2	0.94	0.83	1.07	0.373	0.93	0.81	1.07	0.337	0.82
ApoB/apoA-1 Ratio	0.16	1.19	1.03	1.36	0.016	1.13	0.99	1.30	0.078	0.87
Lp(a) (nmol/L)	88.7	1.22	1.10	1.35	<0.001	1.16	1.04	1.28	0.006	0.646
Log Lp(a) (nmol/L)	1.55	1.24	1.08	1.43	0.002	1.25	1.10	1.42	0.001	0.987

^*Proportional hazards models adjusted for stratification factors and ApoA-1.

^†Hazard ratio is the increase in risk of an increase of one standard deviation.

^‡Test for heterogeneity of treatment effect across values.

ERN = Extended-release niacin; CI = confidence interval; Int. = Interaction between randomization assignment and value